Response of Meningeal Carcinomatosis from Breast Cancer to Capecitabine Monotherapy: A Case Report

A 62-year-old woman with breast cancer received neoadjuvant chemotherapy followed by breast-conserving surgery and sentinel node biopsy. During adjuvant endocrine therapy with aromatase inhibitor, she developed multiple bone metastases. Thereafter, she received tamoxifen and zoledronate therapy. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yumi, Oura, Shoji, Yoshimasu, Tatsuya, Ohta, Fuminori, Naito, Koma, Nakamura, Rie, Hirai, Yoshimitsu, Ikeda, Masako, Okamura, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: January, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573818/
https://www.ncbi.nlm.nih.gov/pubmed/23466482
http://dx.doi.org/10.1159/000345097
Descripción
Sumario:A 62-year-old woman with breast cancer received neoadjuvant chemotherapy followed by breast-conserving surgery and sentinel node biopsy. During adjuvant endocrine therapy with aromatase inhibitor, she developed multiple bone metastases. Thereafter, she received tamoxifen and zoledronate therapy. In May 2011, she developed a tongue deviation and was diagnosed as having meningeal carcinomatosis. The tongue deviation disappeared 3 weeks after taking capecitabine (2,400 mg/day). Magnetic resonance imaging of the brain showed regression of meningeal carcinomatosis. Levels of tumor markers CEA and CA15-3 changed from 96.0 IU/ml and 3.5 ng/ml to 47.0 IU/ml and 1.5 ng/ml, respectively. Progression-free survival with capecitabine monotherapy was 5 months.

Ejemplares similares